Invisioner, I am sure the deletion of your valuabl

Invisioner, I am sure the deletion of your valuable insight post of this private/other drug(s) companies was an oversight. The results should give us all an important insight into the almost exact scenario we are doing at this very exact time with the DSM and FDA. Sadly they were 1:1 on placebo which is a big advantage. A lot is missing from the article I read; like supply chain although we don't know about ours either...

<<Saccovid (known as CD24Fc) is an immunomodulator candidate that targets the innate immune system.

The randomised, placebo-controlled and blinded Phase III study was planned to be conducted in 270 Covid-19 patients, but results were obtained with 203 enrolments, OncoImmune said.

Patient recruitment for the trial has concluded and interim efficacy and safety analyses were carried out upon clinical recovery in 146 participants.

The patients who needed supplemental oxygen, high flow oxygen and non-invasive ventilation were randomly given either standard of care (SOC) plus a single dose of Saccovid or SOC plus placebo.

Data showed that out of 203 participants hospitalised with Covid-19, those who received Saccovid recovered faster and had reduced disease progression to death or respiratory failure by more than 50% versus those on placebo.>>